Compare prices and buy Gonadorelin from 5 research peptide vendors - also called suppliers or sources. Updated daily.
A synthetic decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2, CAS 33515-09-2) identical to the endogenous releasing hormone GnRH (LHRH). Agonizes the pituitary GnRH receptor to drive LH and FSH release. Its human US products have been discontinued, while veterinary formulations remain FDA-approved for cattle.
For research purposes only. Not medical advice.
Gonadorelin is synthetic gonadotropin-releasing hormone (GnRH), carrying the same ten residues in the same order as the hormone the hypothalamus releases. CAS 33515-09-2 is the free base, molecular formula C55H75N17O13, molecular weight about 1182. The literature also calls it luteinizing hormone-releasing hormone (LHRH or LH-RH). The hormonal category page places it on the middle rung of the reproductive axis, between kisspeptin-10 above it and hCG below.
The pituitary reads GnRH as a signal in time. In a 1978 study (Belchetz, Knobil and colleagues, Science), rhesus monkeys whose hypothalamic lesions had abolished gonadotropin release regained pituitary gonadotropin secretion when synthetic GnRH was given intermittently, while a constant infusion failed to restore sustained secretion. In animals already restored on intermittent GnRH, a switch to continuous delivery could produce what the authors called a "desensitization" or "down regulation" of gonadotropin release. They attributed the difference to the pattern of delivery and not to the amount of hormone.
Long-acting GnRH agonists use that second effect. The Lupron Depot label describes leuprolide, a modified GnRH analog, as producing an initial rise in LH and FSH, then decreased concentrations of both under continuous administration. Gonadorelin and leuprolide are both GnRH receptor agonists, and the pattern of exposure decides which response dominates.
FDA designated gonadorelin acetate an orphan drug on April 22, 1987, for induction of ovulation in women with hypothalamic amenorrhea due to a deficiency or absence in the quantity or pulse pattern of endogenous GnRH secretion. Ferring's Lutrepulse, the product carrying that designation, was approved on October 10, 1989.
A retrospective analysis from Massachusetts General Hospital compared 41 women treated in 118 cycles of pulsatile GnRH with 30 women treated in 111 cycles of exogenous gonadotropins (Martin and colleagues, Journal of Clinical Endocrinology and Metabolism, 1993, with NICHD and FDA grant support). Ovulation and conception rates per cycle and per patient did not differ significantly. More than two dominant follicles appeared on ultrasound in 18.9% of pulsatile GnRH cycles against 47.6% of gonadotropin cycles, and the life-table estimate of cumulative conception after six cycles was 96% against 72%. Multiple gestations ran 8.3% against 14.8%, a difference that was not statistically significant.
Drugs@FDA lists two approved human gonadorelin applications, and every strength of both as discontinued.
Discontinued is a marketing status. Under 21 CFR 314.161, FDA must decide whether a withdrawn drug left the market for safety or effectiveness reasons before approving a generic that refers to it, or when someone petitions, and publishes a Federal Register notice when it finds that it did. A full-text search of the federalregister.gov archive, which begins in 1994, found no notice withdrawing either approval and no determination either way for Factrel or Lutrepulse as of October 2026. Neither appears on the 21 CFR 216.24 list of drug products withdrawn for safety or effectiveness, the list that bars compounding.
The veterinary approvals are current. 21 CFR 522.1077 covers gonadorelin injections for cattle as the acetate, the diacetate tetrahydrate and the hydrochloride, restricted to use by or on the order of a licensed veterinarian. The approved uses are treating ovarian follicular cysts and, with cloprostenol or dinoprost, synchronizing estrous cycles to allow fixed-time artificial insemination. DailyMed carries gonadorelin labels for Cystorelin, Fertagyl, OvaCyst, Gonabreed and Factrel, the last a Zoetis product sharing the human product's brand name.
For compounding, gonadorelin appears in neither the September 27, 2024 nor the May 14, 2026 version of FDA's 503A bulk drug substance nominations document, nor on FDA's Category 2 page as of October 21, 2026. Its 503B status is covered on the hormonal category page.
CAS 33515-09-2 is the free base. FDA's Global Substance Registration System files the hydrochloride and several acetates, mono- and di-, anhydrous and hydrated, as separate substances, and 21 CFR 522.1077 equates a given mass of gonadorelin diacetate tetrahydrate with 86% as much gonadorelin. A vendor title such as "Gonadorelin Acetate (GnRH)" therefore states the salt's mass unless the page says the figure is free base. Drugs@FDA, by contrast, lists Factrel's strengths as free-base equivalents.
Vendor titles read Gonadorelin or Gonadorelin Acetate, sometimes with GnRH appended, and papers also use LHRH and LH-RH.
No FDA-approved human gonadorelin product is currently marketed in the US. Two were approved: Factrel, gonadorelin hydrochloride, in 1982, and Lutrepulse, gonadorelin acetate, in 1989 under an orphan designation for inducing ovulation in women with hypothalamic amenorrhea. Drugs@FDA lists both as discontinued, and a search of the Federal Register archive from 1994 on found no notice withdrawing either approval and no determination of whether either left the market for safety or effectiveness reasons. Gonadorelin injections remain FDA-approved for cattle, for ovarian follicular cysts and estrous synchronization, restricted to use by or on the order of a licensed veterinarian. Approvals cover licensed products, not research-grade powder.
Yes. Gonadorelin is synthetic gonadotropin-releasing hormone, a decapeptide with the same sequence as the hormone the hypothalamus releases, and luteinizing hormone-releasing hormone (LHRH or LH-RH) is another name for the same molecule. Its free-base CAS number is 33515-09-2. It is not leuprolide, a GnRH agonist whose label describes a nonapeptide with a modified sequence and greater potency than the natural hormone.
It depends on the pattern of exposure. In a 1978 study in rhesus monkeys whose hypothalamic lesions had abolished gonadotropin release, intermittent synthetic GnRH restored pituitary gonadotropin secretion and a constant infusion did not, and switching restored animals to continuous delivery could desensitize gonadotropin release. Long-acting GnRH agonists rely on that effect. The Lupron Depot label describes an initial rise in LH and FSH followed by decreased concentrations of both under continuous administration of leuprolide.
No. Gonadorelin acetate is a salt, and the acetate and any bound water add mass. FDA's animal-drug regulation for gonadorelin equates a given mass of gonadorelin diacetate tetrahydrate with 86 percent as much gonadorelin. When a vendor titles a product gonadorelin acetate, its milligram figure refers to the salt unless the page states it as free base. CAS 33515-09-2 identifies the free base, and FDA's substance registry files the hydrochloride and the acetates as separate substances.
Gonadorelin is sold by 5 research peptide vendors indexed on PeptideScouter, with 6 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
4 of the 5 indexed vendors currently have Gonadorelin in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
Iron Protocol currently lists Gonadorelin at $3.90/mg, the lowest listed price across 5 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $3.31/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 5 vendors listing Gonadorelin publish a PeptideScouter code, worth 10% to 15% off. Applied, the lowest effective price falls from $3.90/mg listed to $3.31/mg at Iron Protocol. Each vendor's code is shown beside its price in the table above.
Gonadorelin ranges from $3.90/mg to $14.99/mg across 6 listings from 5 research peptide vendors, normalized to USD per milligram and refreshed daily.
5 research peptide vendors currently list Gonadorelin on PeptideScouter, with 4 in stock right now. We track 6 listings across size and kit variants.
Gonadorelin's CAS Registry Number is 33515-09-2.
